2022 American Transplant Congress
Predicted Performance of Bayesian-Based Precision Dosing Software for Tacrolimus
*Purpose: Bayesian-based precision dosing software (BPDS) has been utilized for therapeutic drug monitoring to optimize medication use. However, BPDS for tacrolimus (TAC) is not routinely…2022 American Transplant Congress
Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity
Hokkaido University Hospital, Sapporo, Japan
*Purpose: In the last two decades, the short-term results for kidney transplantation (KTX) have improved owing to the use of calcineurin inhibitors (CNIs). However, long-term…2022 American Transplant Congress
Kidney Transplant Recipients Not Reaching the Expected Post-Transplant Creatinine Range Most Likely Show Calcineurin-Inhibitor Nephrotoxicity Upon Histology
1University Hospital Zürich, Zürich, Switzerland, 2University Hospital Zurich, Zürich, Switzerland
*Purpose: Very recently, our own data suggested that approximately 25% of deceased-donor kidney transplant recipients (KTRs) and 10% of living-donor KTRs don’t reach the expected…2022 American Transplant Congress
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study
*Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…2022 American Transplant Congress
The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation
*Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…2022 American Transplant Congress
Meta-Analysis of the Chronic Exposure to Calcineurin Inhibitors and the Risk for Chronic and End-Stage Kidney Disease in Non-Renal Solid Organ Transplant Recipients
*Purpose: Calcineurin inhibitors (CNI) are standard of care immunosuppressants among all solid organ transplant (SOT) recipients, and the most common side effect is nephrotoxicity. There…2022 American Transplant Congress
Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients
*Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…2022 American Transplant Congress
Impact of Belatacept Conversion on Renal Function and Donor Specific Antibodies in Renal Transplant Recipients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Although associated with nephrotoxicity, calcineurin inhibitors (CNI) have historically been the cornerstone of immunosuppression. Belatacept, a co-stimulation blocker, is FDA-approved for de novo use…2022 American Transplant Congress
Tacrolimus Induces Dedifferentiation of Pancreatic Beta Cells by Inhibition of Calcineurin/NFATc2 and Islet Cell Differentiation Genes
*Purpose: Tacrolimus (FK506) is a potent immunosuppressant widely used for solid organ transplantation to prevent lymphokine gene expression by inhibiting calcineurin (CN) and its downstream…2022 American Transplant Congress
Long-Term Low-Dose Corticosteroid Therapy Can Suppress Calcineurin Inhibitor Induced Nephrotoxicity without Steroid-Related Complication in Living Kidney Transplant Recipient
Sapporo City General Hospital, Sapporo, Japan
*Purpose: The induction of calcineurin inhibitors (CNI) greatly reduced the rate of allograft rejection, although their chronic use resulted in vascular inflammation in kidney transplant…
- 1
- 2
- 3
- …
- 16
- Next Page »